Related Experiment Video

Updated: Dec 28, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.5K

The emerging development of tumor mutational burden in patients with NSCLC

Yu Zhang1, Lifeng Wang1, Rutian Li1

  • 1The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing 210008, PR China.

Future Oncology (London, England)
|February 13, 2020
PubMed

Insights

Tumor mutational burden (TMB) shows promise for predicting immunotherapy response in non-small-cell lung cancer. This study explores TMB

Area of Science:

  • Oncology
  • Immunotherapy
  • Biomarker Discovery

Background:

  • Immunocheckpoint inhibitors (ICIs) targeting PD-1 and CTLA-4 have revolutionized non-small-cell lung cancer (NSCLC) treatment.
  • Tumor mutational burden (TMB) is a key biomarker for predicting ICI response.
  • Recent studies suggest TMB's predictive value may differ between ICI monotherapy and combination therapy.

Purpose of the Study:

  • To re-evaluate the concept of TMB in NSCLC treatment.
  • To investigate TMB signatures, variation factors, racial differences, and tissue vs. blood TMB heterogeneity.
  • To identify novel biomarkers for predicting ICI response beyond TMB.

Main Methods:

  • Analysis of TMB signatures and associated factors.
  • Comparison of tissue-based and blood-based TMB.
  • Exploration of racial variations in TMB.
  • Review of clinical trial data for biomarker identification.

Main Results:

  • TMB's predictive utility may be context-dependent, particularly differing between monotherapy and combination ICI regimens.
  • Identified specific TMB signatures and factors influencing its variation.
  • Highlighted heterogeneity between tissue and blood-based TMB measurements.
  • Revealed potential racial differences in TMB and ICI response.

Conclusions:

  • The clinical utility of TMB requires nuanced understanding, especially concerning ICI combination therapies.
  • Further investigation into TMB's complexities and exploration of additional biomarkers are crucial for optimizing NSCLC immunotherapy.
  • Developing comprehensive predictive models incorporating diverse biomarkers is essential for personalized treatment strategies.
Keywords:
biomarkerimmunocheckpoint inhibitornon-small-cell lung cancertumor mutational burden

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K
Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

11.0K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.1K
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.4K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
53.3K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
9.3K